Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Clin Immunol. 2015 Jul 6;160(2):319–327. doi: 10.1016/j.clim.2015.07.001

Table 5.

Medication changes with normalization of LD in SLE. p values reflect two-tailed χ2 test. p values <0.05 are in italics.

Patient count LD Normalized p
Hydroxychloroquine (+) 37 32 0.90
Hydroxychloroquine (−) 53 44
Mycophenolic mofetil (+) 14 12 0.97
Mycophenolic mofetil (−) 76 64
Mycophenolic acid (+)   3   2 0.79
Mycophenolic acid (−) 87 74
Azathioprine (+)   7   7 0.74
Azathioprine (−) 83 69
Prednisone (+) 41 47 0.043
Prednisone (−) 49 29
Methotrexate (+)   5   3 0.63
Methotrexate (−) 85 73
Cyclophosphamide (+)   2   3 0.52
Cyclophosphamide (−) 88 73
Cyclosporine (+)   4   6 0.75
Cyclosporine (−) 85 83
Rapamycin (+)   0   2 0.155
Rapamycin (−) 90 88
N-acetylcysteine (+)   0   1 1.00
N-acetylcysteine (−) 90 89
Rituximab (+)   0   0 NA
Rituximab (−) 90 76
Anti-TNF (+)   1   0 0.36
Anti-TNF (−) 89 76
NSAIDs (+) 23 12 0.12
NSAIDs (−) 67 64